Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Physical and Mental Metaphors (PMM) task and its validation in schizophrenia: A tool for rapid assessment of figurative language comprehension, between pragmatics and symptoms.

Schizophrenia research. Cognition·2026

Same author

Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics.

European cardiology·2026

Same author

Mechanistic Characterization and Control of Branching in the Polymer of Intrinsic Microporosity PIM-1.

Journal of the American Chemical Society·2026

Same author

Toward Greener Rubber: Impact of Resin Type and Amount on Curing, Network Structure, and Viscoelastic Properties in SBR compounds.

ACS polymers Au·2026

Same author

Apolipoprotein B100 predicts cardiovascular and limb events in type 2 diabetes patients with chronic limb-threatening ischemia.

Cardiovascular diabetology·2026

Same author

Hospice admission of cancer patients receiving disease-modifying therapies near the end of life: implications for eligibility criteria.

Tumori·2026

Search research articles

Related Experiment Videos

Severe leucopenia associated with Sitagliptin use.

Dario Pitocco¹, Francesco Zaccardi, Francesca Martini

¹Department of Internal Medicine, Diabetes Care Unit, Catholic University School of Medicine, Rome, Italy. dario.pitocco@rm.unicatt.it

Diabetes Research and Clinical Practice

|November 2, 2010

Summary

Severe leucopenia, a dangerous drop in white blood cells, was observed in a type 2 diabetes patient treated with the dipeptidyl peptidase-4 (DPP4) inhibitor, Sitagliptin. This case suggests DPP4 inhibitors may cause unexplained blood count issues.

Related Experiment Videos

Area of Science:

Endocrinology
Hematology
Pharmacology

Background:

Type 2 diabetes mellitus (T2DM) management often involves oral hypoglycemic agents.
Dipeptidyl peptidase-4 (DPP4) inhibitors are a class of glucose-lowering drugs widely used for T2DM.
Hematological monitoring is crucial in patients with chronic conditions and those on specific medications.

Observation:

A patient with T2DM developed severe leucopenia, characterized by a significant decrease in white blood cell count.
The onset of leucopenia was temporally associated with the initiation of Sitagliptin therapy, a DPP4 inhibitor.
Other potential causes for leucopenia were ruled out in this clinical presentation.

Findings:

Sitagliptin, a DPP4 inhibitor, is implicated as a potential causative agent for severe leucopenia in this case study.
This adverse event highlights a possible link between DPP4 inhibitor treatment and unexplained hematological abnormalities.
The mechanism underlying Sitagliptin-induced leucopenia requires further investigation.

Implications:

Clinicians should consider DPP4 inhibitors as a potential cause of unexplained leucopenia in diabetic patients.
Enhanced vigilance and monitoring of blood cell counts may be warranted for patients on DPP4 inhibitor therapy.
Further research into the hematological safety profile of DPP4 inhibitors is recommended to elucidate potential risks.